Biohit Oyj (LTS:0DRP) Interest Expense: €-0.20 Mil (TTM As of Dec. 2025)


LTS:0DRP Biohit Oyj LTS:0DRP
78 GF Score
Price €2.85
GF Value €2.70
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Biohit Oyj Interest Expense?

Biohit Oyj LTS:0DRP +4.01% 78 Interest Expense is €-0.20 Mil as of Dec. 2025. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.70 (Fairly Valued). The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biohit Oyj's interest expense for the six months ended in Dec. 2025 was € -0.10 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.20 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biohit Oyj's Operating Income for the six months ended in Dec. 2025 was € 1.80 Mil. Biohit Oyj's Interest Expense for the six months ended in Dec. 2025 was € -0.10 Mil. Biohit Oyj's Interest Coverage for the quarter that ended in Dec. 2025 was 18.00. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biohit Oyj  (LTS:0DRP) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biohit Oyj's Interest Expense for the six months ended in Dec. 2025 was €-0.10 Mil. Its Operating Income for the six months ended in Dec. 2025 was €1.80 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was €1.25 Mil.

Biohit Oyj's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Interest Coverage=-1* Operating Income (Q: Dec. 2025 )/Interest Expense (Q: Dec. 2025 )
=-1*1.8/-0.1
=18.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Biohit Oyj Interest Expense Historical Data

* Premium members only.

The historical data trend for Biohit Oyj's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biohit Oyj Interest Expense Chart

Biohit Oyj Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.29 -0.13 -0.02 -0.05

Biohit Oyj Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.20 -0.10 -0.10 -0.10
LTS:0DRP
78GF Score
Biohit Oyj LTS:0DRP
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biohit Oyj Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.20 Mil mean?
Biohit Oyj (LTS:0DRP) has a Interest Expense of €-0.20 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Biohit Oyj and its competitors.
Is Biohit Oyj's Interest Expense too high?
Biohit Oyj's current Interest Expense is €-0.20 Mil. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Interest Expense compare to ABT and SYK?
Biohit Oyj's Interest Expense of €-0.20 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Biohit Oyj and its competitors. Biohit Oyj's current Interest Expense is €-0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.70, compared to a current price of €2.85 — trading 5.6% above its estimated fair value. The current Interest Expense is €-0.20 Mil. Biohit Oyj's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Interest Expense is €-0.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?

Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued. The current stock price of €2.85 is trading 5.6% above its estimated GF Value™ of €2.70. GuruFocus considers Biohit Oyj to be Fairly Valued.

Key valuation signals for LTS:0DRP:

  • Interest Expense: €-0.20 Mil
  • GF Value™: €2.70 vs. price of €2.85 (5.6% above fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biohit Oyj Business Description

Other Exchanges BIOBV:Finland
Address Laippatie 1, Helsinki, FIN, 00880
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score

Get the complete analysis for LTS:0DRP

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.85
Price
€2.70
GF Value